文献速递消化系统肿瘤

索托拉西布是泛RASG12C抑制剂,可在NRASG12C肿瘤中驱动临床缓解

Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.
PubMed 文献 · Cancer Discov · 2024-01-01

研究假设部分KRASG12C抑制剂可能同时靶向NRASG12C和HRASG12C;体外研究显示索托拉西布对NRASG12C的效力比对KRASG12C或HRASG12C强五倍,结构与交互突变研究提示异构体特异性结合差异由单一氨基酸介导;一例NRASG12C结直肠癌患者接受索托拉西布联合抗EGFR抗体帕尼单抗后获得显著肿瘤缓解。

要点

  • 索托拉西布对NRASG12C的效力比对KRASG12C或HRASG12C强五倍。
  • 阿达格拉西布对KRASG12C高度选择,部分其他抑制剂可抑制NRASG12C和/或HRASG12C。
  • 一例NRASG12C结直肠癌患者经索托拉西布联合帕尼单抗获得显著肿瘤缓解。

核心结论

  • 某些KRASG12C抑制剂可有效靶向所有RASG12C突变,索托拉西布 specifically 是强效NRASG12C抑制剂,能够驱动临床缓解。

研究设计与样本

  • 研究为体外抑制活性比较、结构分析与交互突变研究,并报告一例NRASG12C结直肠癌患者的临床治疗经过。

主要发现

  • 索托拉西布对NRASG12C的效力比对KRASG12C或HRASG12C强五倍。
  • 阿达格拉西布对KRASG12C高度选择,其他一些抑制剂也可强效抑制NRASG12C和/或HRASG12C。
  • 结构与交互突变研究提示异构体特异性结合差异由单一氨基酸介导:KRAS中的组氨酸95(NRAS中为亮氨酸95)。
  • 一例NRASG12C结直肠癌患者接受索托拉西布联合抗EGFR抗体帕尼单抗后获得显著肿瘤缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: KRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors. Because amino acid sequences of the three main RAS isoforms-KRAS, NRAS, and HRAS-are highly similar, we hypothesized that some KRASG12C inhibitors might also target NRASG12C and/or HRASG12C, which are less common but critical oncogenic driver mutations in some tumors. Although some inhibitors, like adagrasib, were highly selective for KRASG12C, others also potently inhibited NRASG12C and/or HRASG12C. Notably, sotorasib was five-fold more potent against NRASG12C compared with KRASG12C or HRASG12C. Structural and reciprocal mutagenesis studies suggested that differences in isoform-specific binding are mediated by a single amino acid: Histidine-95 in KRAS (Leucine-95 in NRAS). A patient with NRASG12C colorectal cancer treated with sotorasib and the anti-EGFR antibody panitumumab achieved a marked tumor response, demonstrating that sotorasib can be clinically effective in NRASG12C-mutated tumors. SIGNIFICANCE: These studies demonstrate that certain KRASG12C inhibitors effectively target all RASG12C mutations and that sotorasib specifically is a potent NRASG12C inhibitor capable of driving clinical responses. These findings have important implications for the treatment of patients with NRASG12C or HRASG12C cancers and could guide design of NRAS or HRAS inhibitors. See related commentary by Seale and Misale, p. 698. This article is featured in Selected Articles from This Issue, p. 695.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Rubinson DA, Tanaka N, Fece de la Cruz F, et al. Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers. Cancer Discov. 2024. PMID: 38236605. doi:10.1158/2159-8290.CD-23-1138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。